NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE
Post-LOEnaproxen sodium and pseudoephedrine hydrochloride
ANDAORALTABLET, EXTENDED RELEASE
Approved
Jun 2022
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.